Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Top 20 Stem Cell Stocks For 2015.

Chicago IL / Research Report Wire / February 27th, 2015 / Institutional Analyst Inc.(IA) announced today released the Top 20 Stem Cell Watch List for 2015 and launching the Stem Cell Stock Review website as a companion site to the Biotech Stock Review which was launched in 2002.

Stem Cell Stock Review:

Stem Cell Magazine:

Biotech Exec TV:

IA is an independent investment research firm founded in 1998, with the launch of the "Internet Stock Review" and additionally provides coverage for companies in a number of distinct industries including; Beverages, Biotech, Internet, Patent Monetization, Alternative Energy, Entertainment, Restaurants, Special Situations and Private Equity.

Extensive stem cell research is being done relating to the treatment of cancer, wound healing, Parkinson's disease, and multiple sclerosis. Due to controversy about embryonic stem cells, many alternative sources for deriving stem cells are being studied, including Autologous Adipose cells, meaning derived from your own fat tissue. Prices in our database range from as low as $0.06 for International Stem Cell ($ISCO), to as high at $98 for BlueBird Bio ($BLUE). Market capitalizations excluding convertible debt, range from under $10 million to as large as $3 billion. Each possess compelling stem cell related technology. The Stem Stock Review was created as a starting point to help those investors searching for lower priced and smaller capitalization companies and is not a recommended list.

Top 20 Stem Cell Stocks for 2015.

*America Cryostem (OTCPK:CRYO) $0.29

Accurexa Inc. (ACXA) $2.95

Asterias Biotherapeutics, Inc. (NYSEMKT:AST) $3.96

Athersys, Inc. (NASDAQ:ATHX) $2.59

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) $3.81

BluebirdBio, Inc. (NASDAQ:BLUE) $93.80

BioTime, Inc. (NYSEMKT:BTX) $4.05

Cesca Therapeutics Inc. (NASDAQ:KOOL) $0.88

*Cellular Biomedicine Group Inc. (NASDAQ:CBMG) $28.46

Cellular Dynamics International, Inc. (NASDAQ:ICEL) $5.11

Cryo-Cell International, Inc. (OTCPK:CCEL) $2.50

Cynata Therapeutics Limited (CYP.AX) $0.94

Cytori Therapeutics, Inc. (NASDAQ:CYTX) $0.73

Fate Therapeutics, Inc. (NASDAQ:FATE) $4.87

International Stem Cell Corporation (OTCQB:ISCO) $0.06

Kadimastem (KDST.TA) $219

Mesoblast Limited (MSB.AX) $4.50

Neuralstem, Inc. (NYSEMKT:CUR) $3.60

Pluristem Therapeutics, Inc. (NASDAQ:PSTI) $3.07

RepliCel Life Sciences Inc. (OTCQB:REPCF) $0.32

Vitro Diagnostics, Inc. (OTCPK:VODG) $0.19

*American Cryostem ($CRYO) $0.29

American Cryostem operates a state-of-the-art, FDA-registered, clinical laboratory dedicated to processing, bio-banking and manufacturing of cellular applications using autologous adipose (fat) tissue and adipose derived stem cells. Through its scientific efforts, the Company has built a strong, strategic portfolio of intellectual property, patent applications, and proprietary operating procedural processes that form its standardized cellular platform. Our growth strategy is centered on fully capitalizing on the scientific breakthroughs that have been rapidly shaping the Regenerative and Personalized Medicine industries; and provide these industries with a standardized cell processing platform to enhance the delivery of healthcare through cellular-based therapies and applications which address burn and wound healing, joint repair, disease treatment and management, and personalized health care.

Accurexa Inc. ($ACXA) $2.95

The Company is focused on developing and commercializing novel neurological therapies based on its proprietary BranchPoint technology delivering therapeutics directly into specific regions of the brain. The BranchPoint device delivers therapeutics through the radial deployment of a flexible delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. Clinicians can "tailor" therapeutic delivery to individual patient anatomy and specific disease targets, which may enhance the efficacy of therapies. The BranchPoint device also gives physicians more precise control of the volume of therapeutics delivered and ensures that therapeutics delivered into the brain stay in the brain, avoiding the problem of reflux out to the brain surface. This modern and "easy to use" technology allows "real-time" monitoring of therapeutic delivery under interventional MRI guidance (iMRI), which can improve the accuracy of therapeutic delivery, reduce the risk of complications, and increase patient safety. The BranchPoint device was developed at the University of California, San Francisco (UCSF) with $1.8 million in funding from the California Institute for Regenerative Medicine (CIRM). It is based on a neurosurgical delivery platform that the Company has exclusively licensed from UCSF. It can enable new approaches to neurological therapy and be modified for the delivery of a broad range of novel therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors and gene therapy vectors.

Asterias Biotherapeutics, Inc. ($AST) $3.96

Asterias Biotherapeutics, Inc., a biotechnology company, focuses on the development of therapeutic products to treat neurology, oncology, cardiology, metabolic diseases, ophthalmology, orthopedics, and blood and vascular diseases. The company focuses on developing pluripotent stem-cell based therapies in neurology and oncology, including AST-OPC1 neural cells to treat spinal cord injury, multiple sclerosis, and stroke; and AST-VAC2, a pluripotent stem cell-derived cancer vaccine. It also has additional product candidates that it intends to develop from various cell types comprising AST-VAC1 for the treatment of cancer; CHND1 for the treatment of osteoarthritis; and CM1 for the treatment of heart failure and myocardial infarction. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is based in Menlo Park, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.

Athersys, Inc. ($ATHX) $2.59

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which has Phase I clinical trials for the patients that have suffered an acute myocardial infarction, and leukemia or other blood-borne cancers; and is ongoing Phase II clinical trials for the patients suffering from inflammatory bowel disease (NYSEARCA:IBD) and ischemic stroke. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing small pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market.

Brainstorm Cell Therapeutics Inc. ($BCLI) $3.81

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.

BluebirdBio, Inc. ($BLUE) $93.80

With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio's clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of beta-thalassemia major; a single-center Phase 1/2 study in France (HGB-205) for the treatment of beta-thalassemia major or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of sickle cell disease (HGB-206). bluebird bio also has a preclinical CAR T cancer immunotherapy program in collaboration with Celgene Corporation, as well as discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies.

BioTime, Inc. ($BTX) $4.05

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTime's focus is on pluripotent stem cell technology based on human embryonic stem ("hES") cells and induced pluripotent stem ("iPS") cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTime's therapeutic and research products include a wide array of proprietary PureStem® progenitors, HyStem® hydrogels, culture media, and differentiation kits. Renevia™ (a HyStem® product), is now in a pivotal trial in Europe as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in the treatment of HIV-related lipoatrophy. In addition, BioTime has developed Hextend®, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend® is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.

Cellular Biomedicine Group Inc. ($CBMG) $28.46

Cellular Biomedicine Group, Inc., a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China. The company operates through two segments, Biomedicine and Consulting. It focuses on developing and marketing cell-based therapies to treat serious chronic and degenerative diseases, such as cancer, osteoarthritis, tissue damage, spinal muscular atrophy, various inflammatory diseases, and joint degeneration and metabolic diseases. The company develops treatments utilizing proprietary cell technologies comprising tumor cell specific dendritic cells for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint disease; human umbilical cord-derived mesenchymal progenitor cells; human embryo-derived motor neuron progenitor precursor cells; and human embryo-derived neuronal progenitor precursor cells for the treatment of central nervous system diseases.

Cellular Dynamics International, Inc. ($ICEL) $5.11

Cellular Dynamics International, Inc. (NYSE:CDI) is a leading developer and manufacturer of fully functioning human cells in industrial quantities to precise specifications. CDI's proprietary iCell Operating System (iCell O/S) includes true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell Products). CDI's iCell O/S products provide standardized, easy-to-use, cost-effective access to the human cell, the smallest fully functioning operating unit of human biology. Customers use our iCell O/S products, among other purposes, for drug discovery and screening; to test the safety and efficacy of their small molecule and biologic drug candidates; for stem cell banking; and in the research and development of cellular therapeutics. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison.

Cryo-Cell International, Inc. ($CCEL) $2.50

Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. The company offers advanced cord tissue service, which stores a section of the umbilical cord tissue, which is a source of mesenchymal stem cells that are used in regenerative medicine research targeting potential therapies for a range of conditions, including heart disease, stroke, multiple sclerosis, and diabetes; and reproductive tissue storage service for cryopreserved embryos, oocytes, and sperm that offers reproductive tissue services, including short and longer-term cryogenic storage, inter-facility transportation coordination, and special quarantined cryogenic storage for infectious disease positive specimens. It stores approximately 300,000 cord blood and cord tissue specimens worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Cynata Therapeutics Limited ($CYP.AX) $0.94

Cynata Therapeutics Ltd is an Australian stem cell and regenerative medicine company developing and commercialising a novel method for producing scalable quantities of mesenchymal stem cells for therapeutic application. The platform technology, Cymerus™, originates from the University of Wisconsin-Madison, a facility that is widely recognised as a world leader in stem cell research. Cynata's proprietary Cymerus™ technology seeks to address a critical shortcoming in existing production methods of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ achieves this by producing a particular type of MSC precursor, called a mesenchymoangioblast (NYSE:MCA). The Cymerus™ MCA technology provides a source of MSCs that are independent of donor limitations and provide a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. The Cymerus™ technology has great potential to create a new standard globally in stem cell therapeutics, with a novel manufacturing technology and an important competitive position.

Cytori Therapeutics, Inc. ($CYTX) $0.73

Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori's proprietary technologies and products.

Fate Therapeutics, Inc. ($FATE) $4.87

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (NYSE:HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person’s lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person’s lifespan. The company’s lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies.

International Stem Cell Corporation ($ISCO) $0.06

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (, and stem cell-based skin care products through its subsidiary Lifeline Skin Care (

Kadimastem ($KDST.TA) $219

Kadimastem uses human stem cells that are differentiated to create medical solutions for diabetes and degenerative diseases of the nervous system and for drug screening. The company's technological platform enables the differentiation of stem cells into a range of functional human cells, including neuron-supporting cells in the brain as well as pancreatic cells that secrete insulin - beta cells. Kadimastem relies on technology that was initially invented at the Weizmann Institute in Prof. Michel Revel's laboratory, and which is now being further developed and advanced in the company's labs at the Weizmann Science Park. Kadimastem is developing two types of medical applications: A. Regenerative medicine, the purpose of which is to repair and replace tissues and organs damaged by disease using healthy cells grown in laboratory conditions, for example, transplantation of insulin-secreting pancreas cells to treat insulin-dependent diabetes, or transplantation of healthy brain-supporting cells to improve survival of nerve cells and treat ALS; B. Drug screening platforms which use functional human cells and tissues to discover new medicinal drugs.

Mesoblast Limited ($MSB.AX) $4.50

Mesoblast Limited is a global leader in regenerative medicine. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late stage product candidates. Mesoblast's allogeneic or 'off-the-shelf' cell product candidates target significantly advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic/inflammatory disorders and oncology/hematology conditions. The lead therapeutic product candidates under investigation include MPC-150-IM for chronic congestive heart failure, in partnership with Teva Pharmaceutical Industries Ltd., MPC-06-ID for chronic discogenic low back pain, MSC-100-IV for acute graft versus host disease, and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy.

Neuralstem, Inc. ($CUR) $3.60

Neuralstem is a dual platform regenerative medicine company. The company's technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (NYSE:CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders.

Neuralstem's small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company's lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (NYSEARCA:MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem's first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic stroke.

Pluristem Therapeutics, Inc. (PSTI) $3.07

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration. Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions, and a seasoned management team.

RepliCel Life Sciences Inc. (OTCQB:REPCF) $0.32

RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address conditions caused by a deficit of healthy cells required for normal healing and function. The company's RCT-01, RCS-01, and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aging skin, and pattern baldness. Shiseido Company, Limited has an exclusive license for RCH-01 in certain Asian countries including Japan , China and South Korea . All product candidates are based on RepliCel's innovative technology utilizing cell populations isolated from a patient's own healthy hair follicles. The company is also developing a propriety injection device optimized for the administration of its products and licensable for use with other dermatology applications. The company's product pipeline is comprised of multiple clinical trials anticipated to launch in 2015 in addition to Shiseido's own clinical trial of RCH-01 and the device in late prototype development

Vitro Diagnostics, Inc. (OTCPK:VODG) $0.19

Vitro Diagnostics, Inc. owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. In 2011, Vitro Biopharma out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies. Vitro Biopharma also owns a pending patent for methods and materials related to treatment of neurological conditions by activation of neural stem cells. Vitro Biopharma's mission is "Harnessing the Power of Cells(NYSE:TM)" for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado. Vitro Biopharma manufactures and sells "Tools for Stem Cell and Drug Development(TM)," including human mesenchymal stem cells and derivatives, the MSC-Gro(TM) Brand of optimized media for MSC self-renewal and lineage-specific differentiation. In addition to our FSH patent licensee, Vitro Biopharma maintains several strategic partnerships including an alliance with Neuromics, Inc. ( Neuromics, Inc. is a primary distributor of Vitro Biopharma products and a well established manufacturer and distributor of a large variety of life science research products especially focused on cell-based assay systems. Also, Vitro Biopharma's CEO is a consultant on an NSF grant at the City College of New York to advise Dr. Lane Gilcrest, Professor of Materials Science and Engineering, and his colleagues regarding the development of novel extracellular materials for use in self-renewal and differentiation of mesenchymal stem cells.

About Institutional Analyst

Institutional Analyst Inc. (IA), an independent investment research and investor relations firm. IA is a leading publisher of news, perspective and market intelligence reports on the equity markets. Working with publicly traded corporations, the firm seeks out small-cap companies which have products and/or services and management which can best be described as "best of breed." To best align itself with shareholders, IA typically seeks to have 90% of its retainer, represented by an equity stake in its client companies. When compensated for providing research reports or coverage, IA will provide all details on its website or report in a manner fully compliant with current regulatory guidelines. While we are not an impartial organization, we endeavor our best to initiate research coverage on companies which believe may perform well after initiating coverage.

Senior executives at publicly traded companies seeking to expand their awareness amongst investors who have an interest in stem cell and biomedical stocks, or to be interviewed on Biotech Exec TV may contact us at the number listed below, initial contact by email is preferred.

Founded in 1995 and based in Chicago, the heart of the trading industry, Institutional Analyst has offices in Beverly Hills, CA, Chicago IL, Delray Beach, FL and Port Jefferson, NY.

About The Stem Cell Stock Review

The Stem Stock Review website provides individual news feeds for each company on the Watch List, enabling investors to easily follow the entire group with a single visit. Each Friday we issue a weekly "head-line" wrap up of stem cell industry news via our free newsletter. Also included are links to third party industry expert websites and leading news sources such as the Life Sciences Report, Edison Research, Futurity, the Timmerman Report, Fierce Biotech, BioMed Reports, Science Daily and research reports from a broad spectrum of Wall Street sources.

Stem Cell Stock Review Website:

The Stem Cell Stock Review additionally has a Flipboard powered magazine which archives a collection of stem cell industry related articles from over 100 sources and can be found here:

Stem Cell Stock Review Magazine:

The Stem Cell Stock Review additionally has an online Internet TV channel called Biotech Exec TV, which hosts interviews with industry and Wall Street experts.

Biotech Exec TV:


Roland Rick Perry

Managing Director, Institutional Analyst Inc.

email: (preferred contact method)

Phone: 310-594-8062

Seeking Alpha:

Stock Twits:

Harvest Exchange:

SEC guide for Microcap stocks:

All prices above as of 2/24/2015

*American CryoStem was added to Watch List at $0.21 in February of 2015. Cellular Biosciences was added to to the Watch List in January of 2015 at $16.59.

Disclosure: The author has no positions in any stocks mentioned, but may initiate a long position in CRYO over the next 72 hours.